US Patent

US12102696 — Radiolabeling and formulation for scale up of 64Cu-DOTATATE

Formulation · Assigned to Curium US LLC · Expires 2041-09-03 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for creating a large quantity of a radioactive diagnostic agent used in PET scans to locate certain types of tumors.

USPTO Abstract

The present disclosure relates to methods to create a robust procedure capable of supplying commercial quantities of a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.

Drugs covered by this patent

Patent Metadata

Patent number: US12102696
Jurisdiction: US
Classification: Formulation
Expires: 2041-09-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Curium US LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.